Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 5/20 | 0.82 |
| ▸ | FABP3 | P05413 | 4/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.64 |
| ▸ | FABP5 | Q01469 | 4/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | PRNP | P04156 | 1/20 | 0.59 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.59 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAP2 | P11137 | 1/20 | 0.53 |
| ▸ | DHODH | Q02127 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21083000 | 0.90 | FABP4 (1.00) | FABP4FABP3ALDH1A1KDM4EPLA2G2A | |
| SCHEMBL2825174 | 0.86 | ALDH1A1 (0.76) | FABP4FABP3ALDH1A1KDM4EPLA2G2A | |
| SCHEMBL31442524 | 0.86 | FABP3 (0.62) | FABP4FABP3ALDH1A1KDM4EPLA2G2A | |
| SCHEMBL31442453 | 0.85 | GAA (0.62) | FABP4FABP3ALDH1A1KDM4EPLA2G2A | |
| SCHEMBL2822459 | 0.85 | GAA (0.62) | FABP4FABP3ALDH1A1KDM4EPLA2G2A | |
| SCHEMBL2824337 | 0.84 | FABP4 (0.65) | FABP4FABP3ALDH1A1KDM4EPLA2G2A | |
| SCHEMBL2822472 | 0.84 | ALDH1A1 (1.00) | FABP4FABP3ALDH1A1KDM4ENPSR1 | |
| SCHEMBL3322903 | 0.84 | FABP4 (0.73) | FABP4FABP3ALDH1A1KDM4EPLA2G2A | |
| SCHEMBL2822065 | 0.83 | FABP4 (0.59) | FABP4FABP3ALDH1A1KDM4EPLA2G2A | |
| SCHEMBL3318172 | 0.83 | FABP4 (0.72) | FABP4FABP3ALDH1A1KDM4EPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809605-B1 | QUINOLINES AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | claimed |
| EP-1809605-A1 | QUINOLINE AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | F. Hoffmann-Roche AG (CH) | 2007-07-25 | — | — | EP | claimed |
| WO-2006048146-A1 | QUINOLINE AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-11 | — | — | WO | claimed |
| US-20060094754-A1 | Quinolines as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. | 2006-05-04 | — | — | US | claimed |
| US-20150164910-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-06-18 | — | — | US | disclosed |
| US-20150164910-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-06-18 | — | — | US | disclosed |
| US-20150164910-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-06-18 | — | — | US | disclosed |
| US-8865739-B2 | Substituted heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140107155-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8664399-B2 | Substituted heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130102632-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| EP-1809605-B1 | QUINOLINES AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| US-20100125091-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | US | disclosed |
| WO-2010056865-A1 | QUINOLINE DERIVATIVES AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-7576217-B2 | Quinolines as allosteric enhancers of the GABAB receptors | HOFFMAN-LA ROCHE INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1809605-A1 | QUINOLINE AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | F. Hoffmann-Roche AG (CH) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006048146-A1 | QUINOLINE AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-11 | — | — | WO | disclosed |
| US-20060094754-A1 | Quinolines as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107155-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNH2, KCNJ2, CACNA1E | FABP4 3868/4885FABP3 1216/4885ALDH1A1 2215/4885 |
| US-20060094754-A1 | Quinolines as allosteric enhancers of the GABAB receptors | GABRB1, GABRB2, GABRA1 | FABP4 3800/4885FABP3 2743/4885ALDH1A1 925/4885 |
| US-20100125091-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNH2, KCNJ2, CACNA1E | FABP4 3868/4885FABP3 1216/4885ALDH1A1 2215/4885 |
| US-20150164910-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE | EIF2AK2, RNASE1, HAVCR2 | FABP4 4662/4885FABP3 2738/4885ALDH1A1 4417/4885 |
| US-20130102632-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNH2, KCNJ2, CACNA1E | FABP4 3868/4885FABP3 1216/4885ALDH1A1 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.